Use of liquid biopsy in monitoring therapeutic resistance in EGFR oncogene addicted NSCLC
Liquid biopsy has emerged as a minimally invasive alternative to tumor tissue analysis for the management of lung cancer patients, especially for epidermal growth factor receptor (EGFR) oncogene addicted tumor. In these patients, despite the clear benefits of tyrosine kinase inhibitors therapy, the...
Main Authors: | Marialucia Iacovino, Vincenza Ciaramella, Fernando Paragliola, Gabriella Suarato, Gesualdina Busiello, Francesca Sparano |
---|---|
Format: | Article |
Language: | English |
Published: |
Open Exploration Publishing Inc.
2020-12-01
|
Series: | Exploration of Targeted Anti-tumor Therapy |
Subjects: | |
Online Access: | https://www.explorationpub.com/Journals/etat/Article/100224 |
Similar Items
-
Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example
by: Bing Wei, et al.
Published: (2019-05-01) -
Combination of Osimertinib and Anlotinib May Overcome the Resistance Mediated by in cis EGFR T790M-C797S in NSCLC: A Case Report
by: Zhou R, et al.
Published: (2021-04-01) -
Personalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series
by: Daliborka Bursac, et al.
Published: (2021-05-01) -
Osimertinib alone as second-line treatment for brain metastases (BM) control may be more limited than for non-BM in advanced NSCLC patients with an acquired EGFR T790M mutation
by: Changhui Li, et al.
Published: (2021-05-01) -
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsy
by: Isa Mambetsariev, et al.
Published: (2018-03-01)